H-GFKQSSKAL-OH

Ref. 3D-PP46558

Product Information

• Name: H-GFKQSSKAL-OH
• Synonyms: NH2-Gly-Phe-Lys-Gln-Ser-Ser-Lys-Ala-Leu-OH

Description

Peptide H-GFKQSSKAL-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using H-GFKQSSKAL-OH include the following: Induction of BCR-ABL-specific immunity following vaccination with chaperone-rich cell lysates derived from BCR-ABL+ tumor cells Y Zeng , MW Graner, S Thompson, M Marron - Blood, 2005 - ashpublications.orghttps://ashpublications.org/blood/article-abstract/105/5/2016/20299 CTLs specific for bcr-abl joining region segment peptides fail to lyse leukemia cells expressing p210 bcr-abl protein W Chen, H Qin, VA Reese - Journal of , 1998 - journals.lww.comhttps://journals.lww.com/immunotherapy-journal/abstract/1998/07000/CTLs_Specific_for_bcr_abl_Joining_Region_Segment.3.aspx Peptide vaccines for myeloid leukaemias T Dao, DA Scheinberg - Best Practice & Research Clinical Haematology, 2008 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S1521692608000510 The Imatinib and Nilotinib Induced Modulation of the Proteasomal Activity and Antigen Processing in Chronic Myeloid Leukemia Cells SAE Held, A Heine , S Tenzer , A Bringmann, H Schild - 2011 - ashpublications.orghttps://ashpublications.org/blood/article-abstract/118/21/2748/70642 Soluble HLA/peptide monomers cross-linked with co-stimulatory antibodies onto a streptavidin core molecule efficiently stimulate antigen-specific T cell responses S Rusakiewicz, G Aubert, RE Clark, AJ Madrigal - Cancer immunology , 2009 - Springerhttps://link.springer.com/article/10.1007/s00262-009-0711-x BCR/ABL-specific CD8+ T cells can be detected from CML patients, but are only expanded from healthy donors S Rusakiewicz, A Madrigal, P Travers - Cancer immunology , 2009 - Springerhttps://link.springer.com/article/10.1007/s00262-009-0703-x Imatinib Mesylate and Nilotinib Affect the MHC-Class I Presentation by Modulating the Proteasomal Processing of Antigenic Peptides. S Held, S Tenzer , T Ruckrich, K von Schwarzenberg - Blood, 2009 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0006497119549801 Immunotherapyinchronicmyeloidleukemia RE Clark - Chronic Myeloproliferative Disorders, 2013 - taylorfrancis.comhttps://www.taylorfrancis.com/chapters/edit/10.3109/9780203091616-13/immunotherapyinchronicmyeloidleukemia-richard-clark A pilot vaccination trial of synthetic analog peptides derived from the BCR-ABL breakpoints in CML patients with minimal disease PG Maslak, T Dao, M Gomez, S Chanel, J Packin - Leukemia, 2008 - nature.comhttps://www.nature.com/articles/leu20087 Circulating bcr-abl-specific CD8+ T cells in chronic myeloid leukemia patients and healthy subjects NM Butt, JM Rojas, L Wang, SE Christmas - , 2005 - haematologica.orghttps://www.haematologica.org/article/view/3687 The 'peptidome'of tumour-derived chaperone-rich cell lysate anti-cancer vaccines reveals potential tumour antigens that stimulate tumour immunity MW Graner, A Romanoski - International Journal of , 2013 - Taylor & Francishttps://www.tandfonline.com/doi/abs/10.3109/02656736.2013.793406 Infusion of bcr/abl peptide-reactive donor T cells to achieve molecular remission of chronic myeloid leukemia after CD34+ selected allogeneic hematopoietic cell M Bornhauser, C Thiede , J Babatz, J Schetelig, T Illmer - Leukemia, 2006 - nature.comhttps://www.nature.com/articles/2404383 Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules M Bocchia, PA Wentworth, S Southwood, J Sidney - 1995 - ashpublications.orghttps://ashpublications.org/blood/article-abstract/85/10/2680/123090 Dendritic-cell-peptide immunization provides immunoprotection against bcr-abl -positive leukemia in mice L He, H Feng, A Raymond, M Kreeger, Y Zeng - Cancer Immunology , 2001 - Springerhttps://link.springer.com/article/10.1007/PL00006680 Chaperone-rich cell lysate embedded with BCR-ABL peptide demonstrates enhanced anti-tumor activity against a murine BCR-ABL positive leukemia KL Kislin, MT Marron , G Li, MW Graner - The FASEB , 2007 - Wiley Online Libraryhttps://faseb.onlinelibrary.wiley.com/doi/abs/10.1096/fj.06-7843com Clinical evaluation of BCR-ABL peptide immunisation in chronic myeloid leukaemia: results of the EPIC study JM Rojas, K Knight, L Wang, RE Clark - Leukemia, 2007 - nature.comhttps://www.nature.com/articles/2404858 BCR-ABL fusion regions as a source of multiple leukemia-specific CD8+ T-cell epitopes JH Kessler, SA Bres-Vloemans, PA Van Veelen - Leukemia, 2006 - nature.comhttps://www.nature.com/articles/2404354 Simultaneous cytokine analysis by cytometric bead array for the detection of leukaemia-reactive T cells in patients with chronic myeloid leukaemia J Westermann, A van Lessen - British journal of , 2006 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1111/j.1365-2141.2005.05844.x Anti Leukemic T Cells in Myeloid Neoplasia: Abnormal Cytokine Secretion Patterns May Prevent Immunological Detection and Possibly Reflect Functional Impairment. J Westermann, A van Lessen, T Terwey, P Le Coutre - 2006 - ashpublications.orghttps://ashpublications.org/blood/article-abstract/108/11/1740/127037 T-cell responses in chronic myeloid leukaemia HM Abu-Eisha - 2005 - search.proquest.comhttps://search.proquest.com/openview/f02b0dd94854389e9b7069fc2f011f76/1?pq-origsite=gscholar&cbl=51922&diss=y Proteosomal degradation of BCR/ABL protein can generate an HLA-A* 0301-restricted peptide, but high-avidity T cells recognizing this leukemia-specific antigen were EF Posthuma, CA Van Bergen , MG Kester - , 2004 - haematologica.orghttps://www.haematologica.org/article/view/3217 Identification of EGFRvIII-derived CTL epitopes restricted by HLA A0201 for dendritic cell based immunotherapy of gliomas A Wu, J Xiao, L Anker, WA Hall, DS Gregerson - Journal of neuro , 2006 - Springerhttps://link.springer.com/article/10.1007/s11060-005-3280-7

• Brand: Biosynth